Clinical Trials in Georgia

Showing 3441-3460 of 16,324 trials

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

NCT06104969

This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions

Diabetic Foot UlcerDiabetic FootDiabetes

University of Michigan5,000 participantsStarted Jun 2023

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +5 more locations

COMPLETEDPhase 265 miles

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.

Severe Postpartum Depression

Supernus Pharmaceuticals, Inc.21 participantsStarted Dec 2015

Atlanta, Georgia, United States • Worcester, Massachusetts, United States • Chapel Hill, North Carolina, United States +1 more locations

COMPLETEDPhase 165 miles

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Find Trials by Condition in Georgia

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Study of Anti-Malarials in Incomplete Lupus Erythematosus

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency